Corporation, a biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary therapeutics, finds itself at a critical juncture as it navigates the ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

More than 100 projects have received support as part of the 2024 European Research Council (ERC) proof of concept competition ...

Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetesRUTHERFORD, N.J., Jan. 29, 2025 ...

Imagine you’re a landowner with dozens or hundreds of mature hardwood trees — not a stretch, since the majority of forestland in the U.S. is privately owned. If you want to know the trees’ value, you’ ...

Monday's tech sector meltdown, triggered by DeepSeek's AI breakthrough, caused collateral damage to share prices in the ...

Four publications in the journal Nuclear Fusion detail the Company’s novel system architecture and its ability to address ...

The partnership will combine IIT Guwahati's expertise in cutting-edge research with Miraclus Orthotech's industry leadership.

Massachusetts-based Veir develops superconducting solutions for the data center sector. The company intends to use the funds ...

REGINA — Saskatchewan Pulse Growers is close to signing a new crop breeding agreement with the University of Saskatchewan’s ...

Zenas BioPharma, Inc.’s ZBIO share price has surged by 13.37%, which has investors questioning if this is right time to sell.

With the establishment of the Texas Space Commission in 2024 through House Bill 3447 and rapid innovations toward space commercialization ...